News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Bleeding Disorders
Hereditary Angioedema (HAE)
Fluid Management


16 May 2016 CSL Behring Commemorates 2016 hae day :-) with Partnerships, Sponsorships and Hereditary Angioedema Awareness Events

CSL Behring supports HAE Day thru our continued partnership with HAEi & global awareness event sponsorships.

> Read More
24 February 2016 CSL Behring Adds Isoagglutinin Reduction Step to Privigen® Manufacturing Process

Global biotherapeutics leader CSL Behring today announced an enhancement to its manufacturing process for Privigen® with the addition of the Ig IsoLo® step.

> Read More
23 February 2016 First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia

Global biotherapeutics leader CSL Behring today announced an increase in the global supply of Privigen® as the first export has been shipped from a new state-of-the-art manufacturing facility in Broadmeadows, Melbourne, Australia.

> Read More
08 December 2015 CSL Behring Expands Operations to Russia

Global biotherapeutics leader CSL Behring announced today its latest geographic expansion to provide more patients with greater access to treatment by opening operations in Russia. This is particularly significant in Russia where the healthcare system has some unmet needs for state-of-the-art biotherapies and blood plasma products.

> Read More
28 September 2015 New Clinical Data on Treatment to Slow the Progression of Emphysema in Patients with Alpha-1 Antitrypsin Deficiency Presented at European Respiratory Society International Congress in Amsterdam

CSL Behring today hosted a symposium highlighting an option to slow the progression of emphysema in adults with documented severe alpha-1 antitrypsin deficiency (AATD), during the European Respiratory Society (ERS) International Congress, which is being held from 26-30 September in Amsterdam, Netherlands. AATD is a hereditary condition marked by a lack of the alpha-1 antitrypsin protein, whose main function is to protect the lungs from inflammation.

> Read More
Page 1 of 6 Next | Last

LinkedIn Twitter Facebook Google+